Search details
1.
Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidates.
AIDS Care
; : 1-7, 2024 Apr 12.
Article
in English
| MEDLINE | ID: mdl-38606559
2.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Antimicrob Agents Chemother
; 67(4): e0005323, 2023 04 18.
Article
in English
| MEDLINE | ID: mdl-36995219
3.
Pregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN 052.
AIDS Care
; 35(6): 824-832, 2023 06.
Article
in English
| MEDLINE | ID: mdl-36524872
4.
Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Ann Intern Med
; 175(4): 479-489, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35099992
5.
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
J Infect Dis
; 226(12): 2170-2180, 2022 12 13.
Article
in English
| MEDLINE | ID: mdl-36240386
6.
Prevention of HIV Transmission and the HPTN 052 Study.
Annu Rev Med
; 71: 347-360, 2020 01 27.
Article
in English
| MEDLINE | ID: mdl-31652410
7.
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
J Antimicrob Chemother
; 77(2): 500-506, 2022 02 02.
Article
in English
| MEDLINE | ID: mdl-34791296
8.
A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.
Br J Clin Pharmacol
; 88(10): 4623-4632, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35949044
9.
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
AIDS Behav
; 26(12): 4107-4114, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35687192
10.
Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial.
Clin Trials
; 19(6): 605-612, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36053045
11.
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
J Infect Dis
; 224(9): 1581-1592, 2021 11 16.
Article
in English
| MEDLINE | ID: mdl-33740057
12.
Evaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052.
Clin Infect Dis
; 72(1): 30-37, 2021 01 23.
Article
in English
| MEDLINE | ID: mdl-31922537
13.
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
Clin Infect Dis
; 70(2): 319-322, 2020 01 02.
Article
in English
| MEDLINE | ID: mdl-31125395
14.
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
AIDS Behav
; 24(9): 2520-2531, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32052214
15.
Phylogenetic Methods Inconsistently Predict the Direction of HIV Transmission Among Heterosexual Pairs in the HPTN 052 Cohort.
J Infect Dis
; 220(9): 1406-1413, 2019 09 26.
Article
in English
| MEDLINE | ID: mdl-30590741
16.
Antiretroviral Therapy for the Prevention of HIV-1 Transmission.
N Engl J Med
; 375(9): 830-9, 2016 09 01.
Article
in English
| MEDLINE | ID: mdl-27424812
17.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS Med
; 15(11): e1002690, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30408115
18.
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Ann Intern Med
; 167(6): 384-393, 2017 Sep 19.
Article
in English
| MEDLINE | ID: mdl-28828489
19.
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
J Infect Dis
; 215(2): 238-246, 2017 Jan 15.
Article
in English
| MEDLINE | ID: mdl-27811319
20.
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
N Engl J Med
; 369(18): 1715-25, 2013 Oct 31.
Article
in English
| MEDLINE | ID: mdl-24171517